Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Reflections on key issues in clinical research design of new TCM drugs for ankylosing spondylitis].

Created on 18 Nov 2026

Authors

Shuang Xiao, Jin-Lian Cheng, Xin-Cai Xie, Qin Zhang, Xue-Qi Zhu, Yan Wang, Yue Sun

Published in

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. Volume 51. Issue 20. Pages 6007-6015.

Abstract

Ankylosing spondylitis is a chronic inflammatory autoimmune disease, and existing treatment options face significant limitations in clinical practice. Traditional Chinese medicine offers unique advantages. However, the development of new TCM drugs in this field remains relatively lagging, and there is still a lack of targeted technical guidelines for clinical research in China. Guided by the General principles for clinical research of new traditional Chinese medicines, and drawing on the Guideline on the clinical investigation of medicinal products for the treatment of axial spondyloarthritis, and the Assessment of spondyloarthritis international society(ASAS) handbook: a guide to assess spondyloarthritis, this article systematically outlines key aspects of clinical trial design for new TCM drugs for ankylosing spondylitis. The discussion covers seven key areas: clinical positioning, target population, efficacy evaluation, safety considerations, trial interventions, treatment duration and visit schedules, overall study design, and quality control measures, aiming to provide methodological insights for the clinical research of this category of new TCM drugs. This article proposes that in the absence of specific guidelines, a series of scientific design measures can be employed to mitigate registration risks, such as adopting enrichment strategies to precisely identify target populations, establishing a composite endpoint evaluation system that incorporates both internationally recognized ASAS efficacy criteria and TCM syndrome efficacy indicators as primary endpoints, and exploring an evidence chain combining RCTs with real-world studies to form a comprehensive data support system.

PMID:
43045141
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement